News
-
-
-
COMMUNIQUÉ DE PRESSE
Rapport Financier Semestriel FY26-S1
-
COMMUNIQUÉ DE PRESSE
Approval of the Offer Document concerning the voluntary tender offer for shares of NEXT RE SIIQ S.p.A.
Approval of the Offer Document for voluntary tender offer for shares of NEXT RE SIIQ S.p.A. by CPI Property Group. Offer price Euro 3.00. Acceptance period 20 Apr - 15 May 2026 -
-
-
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: Correction of a release from 16/04/2026, 19:17 CET/CEST - Drägerwerk AG & Co. KGaA: Preliminary figures Q1 2026: Earnings significantly above prior year
Drägerwerk AG & Co. KGaA reports Q1 2026 preliminary results: strong earnings growth, net sales increase, and positive EBIT margin. Forecast for 2026 includes higher sales and EBIT margin -
COMMUNIQUÉ DE PRESSE
AB Science fait le point sur son programme de développement clinique
AB Science obtient une assurance d'essais cliniques de 25 millions d'euros pour son étude de phase III sur la sclérose latérale amyotrophique et met en place une suspension temporaire de ses essais cliniques en Europe -
-
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: Drägerwerk AG & Co. KGaA: Preliminary figures Q1 2026: Earnings significantly above prior year
Drägerwerk AG & Co. KGaA reports significant earnings growth in Q1 2026, with net sales up by 6.9%. Positive trends in both medical and safety divisions drive increase in EBIT and order intake
